EXEL News and Press, Exelixis Inc. From 01/16/26

2026-01-16 13:49:19 ET More on healthcare stocks XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? Cardinal Health, Inc. (CAH) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Cardinal Health, Inc. (CAH) Presents at 44th Annual...

2026-01-13 00:45:57 ET Exelixis, Inc. (EXEL) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 8:15 PM EST... Read the full article on Seeking Alpha For further details see: Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12 02:16:04 ET Read the full article on Seeking Alpha For further details see: FPX: Leading IPO ETF With A Few Unexpected Holdings

– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and we...

2026-01-08 10:05:33 ET Robert Burns from H.C. Wainwright issued a price target of $52.00 for EXEL on 2026-01-08 14:30:04. The adjusted price target was set to $52.00. At the time of the announcement, EXEL was trading at $44.79. The overall price target consensus is at $4...

2026-01-08 05:35:00 ET The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the industry performed relatively well and appear to be solid buy-and-hold options. And we're not just talking about the most prominent, best-known...

2026-01-07 09:14:28 ET More on Exelixis, Natera Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day - Slideshow Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at...

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medi...

– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Heal...

2026-01-05 13:26:16 ET More on Exelixis Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day - Slideshow Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D...